Submit your email to push it up the queue
Stiefel Laboratories, Inc., a prominent name in dermatological care, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1847, the company has established itself as a leader in the pharmaceutical industry, focusing primarily on skin health and dermatology. Stiefel is renowned for its innovative products, including prescription medications, over-the-counter treatments, and skincare solutions that cater to a diverse range of skin conditions. Their commitment to research and development has led to significant advancements in dermatological therapies, setting them apart in a competitive market. With a strong market position, Stiefel Laboratories has achieved notable milestones, including numerous product launches that have transformed patient care in dermatology. Their dedication to quality and efficacy continues to drive their success in the industry.
How does Stiefel Laboratories, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Stiefel Laboratories, Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Stiefel Laboratories, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of GSK plc, and as such, it inherits emissions data and climate commitments from its parent organisation. While no absolute emissions figures are provided, Stiefel Laboratories is aligned with GSK plc's sustainability initiatives, which include various climate commitments. These initiatives are part of GSK's broader strategy to reduce carbon emissions across its operations, including Scope 1, 2, and 3 emissions. Stiefel Laboratories has not specified any reduction targets or achievements independently, but it follows the climate pledges and targets set by GSK plc. This includes participation in initiatives such as the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and RE100, which aim to drive significant reductions in greenhouse gas emissions. As a subsidiary, Stiefel Laboratories is committed to supporting GSK's overarching goals for sustainability and climate action, although specific metrics and targets for Stiefel itself are not detailed.
Access structured emissions data, company-specific emission factors, and source documents
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Stiefel Laboratories, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.